drug
ketamine
Phase 3updated 3mo agoby $NRXP NRX Pharmaceuticals, Inc.
Phase 3community read0 votes
🐶 often sniffed alongside
top 8- drugKETAMINE HYDROCHLORIDE59 co-mentions · 32 sources
- drugKetalar59 co-mentions · 32 sources
- tagApproval58 co-mentions · 29 sources
- tagRecall10 co-mentions · 10 sources
- tagPain4 co-mentions · 1 sources
- drugflumazenil4 co-mentions · 4 sources
- tagOncology2 co-mentions · 1 sources
- tagBreast Cancer2 co-mentions · 1 sources
all catalysts(1)
Trials studying ketamine
- phase3A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- phase4A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
- —Anesthetics and Analgesics in Children
- phase3Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches
- phase1Ketamine Biomarker Validation
- phase4A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
- phase1Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
- —Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
News(5)
- Lilly’s $3.8B psychedelics bet won’t open the M&A floodgatesEli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…biospace · 27d ago
- ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsAfter Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.fiercebiotech · 1mo ago
- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsThe latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.biopharma_dive · 1mo ago
- Another big premium hike on the horizonFDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning Roundsstat · 1mo ago
- Opinion: The psychedelic revolution is leaving behind people of colorPsychedelics’ potential as a form of treatment is virtually unmatched. But their promise faces both scientific uncertainty and thorny political questions.stat · 3mo ago
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that